sm-346 has been researched along with Parkinson-Disease--Secondary* in 1 studies
1 other study(ies) available for sm-346 and Parkinson-Disease--Secondary
| Article | Year |
|---|---|
[Effect of afobazole and levodopa on the activity of proline-specific proteinases and adenosine deaminase in blood serum and brain structures of rats with experimental Parkinson's syndrome induced by systemic administration of rotenone].
Rats with experimental Parkinson's syndrome induced by seven-day intraperitoneal administration of rotenone at a dose of 2.75 mg/kg have an increased activity of prolylendopeptidase (EC 3.4.21.26, PREP) in blood serum and a decreased activity of adenosine deaminase (EC 3.5.4.4, ADA) in serum and in the prefrontal cortex. PREP and ADA activity in other brain structures (in the striatum, hypothalamus and hippocampus) did not change; dipeptidyl peptidase IV activity (EC 3.4.14.5, DPP-4, CD26) also remained constant in serum and in all the brain structures investigated. Afobazole and levodopa, which exhibit antiparkinsonian activity in this model of Parkinson's syndrome, decrease elevated PREP activity in serum and increase reduced ADA activity in the prefrontal cortex of rats with the experimental pathology. Meanwhile, treatment with the study drugs was associated with a decrease of ADA activity in the other brain structures.. U krys s éksperimental'nym parkinsonicheskim sindromom (PS), vyzvannym semidnevnym vnutribriushinnym vvedeniem rotenona v doze 2,75 mg/kg, nabliudaetsia povyshenie aktivnosti proliléndopeptidazy (EC 3.4.21.26, PÉP) v syvorotke krovi i snizhenie aktivnosti adenozindezaminazy (EC 3.5.4.4, ADA) v syvorotke krovi i frontal'noĭ kore golovnogo mozga. Aktivnost' PÉP i ADA v drugikh strukturakh golovnogo mozga (striatume, gipotalamuse, gippokampe), kak i aktivnost' dipeptidilpeptidazy IV (EC 3.4.14.5, DPP-4, CD26) vo vsekh issleduemykh strukturakh golovnogo mozga i syvorotke krovi zhivotnykh s éksperimental'noĭ patologieĭ dostoverno ne izmeniaetsia. Afobazol i levodopa, proiavliaiushchie protivoparkinsonicheskuiu aktivnost' na dannoĭ modeli PS, snizhaiut povyshennuiu aktivnost' PÉP v syvorotke krovi zhivotnykh i povyshaiut snizhennuiu aktivnost' ADA vo frontal'noĭ kore krys s éksperimental'noĭ patologieĭ. Pri étom na fone izuchaemykh preparatov zaregistrirovano snizhenie aktivnosti ADA v drugikh strukturakh golovnogo mozga. Topics: Adenosine Deaminase; Animals; Benzimidazoles; Brain; Dipeptidyl Peptidase 4; Levodopa; Morpholines; Parkinson Disease, Secondary; Proline; Prolyl Oligopeptidases; Rats; Rotenone; Serine Endopeptidases; Serum | 2017 |